Heron Therapeutics (NASDAQ:HRTX) reported fourth-quarter and full-year 2025 results while outlining plans to increase commercial investment in 2026 to build on what management described as an ...
Heron Therapeutics (HRTX) reported robust financial results for Q4 2025, highlighted by significant growth in its acute care portfolio. The company’s net revenues for the full year reached $154.9 ...
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2025 Earnings Call Transcript August 8, 2025 Heron Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.02 EPS, expectations were $-0.01.
Image source: The Motley Fool. Heron Therapeutics (NASDAQ:HRTX) delivered operational and financial milestones, including full-year adjusted EBITDA above guidance and net product revenue gains led by ...
CARY, N.C., Aug. 8, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that it has rescheduled its release of ...
Operator: Thank you for standing by and welcome to Heron Therapeutics Third Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, ...
Thank you for standing by, and welcome to the Heron Therapeutics Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. And now I'd ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results